1. Protein Tyrosine Kinase/RTK
  2. VEGFR
  3. Aflibercept

Aflibercept  (Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1)

目录号: HY-108801 纯度: ≥97.0%
COA

Aflibercept (VEGF Trap) 是由 VEGFR1 和 VEGFR2 的 Ig 结构域与人 IgG1 的 Fc 域融合而成的可溶性诱饵 VEGFR。Aflibercept 抑制 VEGF 信号通过抑制 VEGF 参与调控的通路。Aflibercept 可以用于老年性黄斑变性 (AMD) 和心血管疾病的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Aflibercept Chemical Structure

Aflibercept Chemical Structure

CAS No. : 862111-32-8

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
500 μg ¥4850
In-stock
1 mg ¥7800
In-stock
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Aflibercept:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease[1][2][3].

体外研究
(In Vitro)

Aflibercept (500 μg/mL; 24 h and 7 d) shows no toxicity on RPE cells, neither in MTT-assay nor in trypan blue exclusion assay[1].
Aflibercept (500 μg/mL; 24 h) shows a statistically significant effect on wound healing compared with control in the confluent RPE cell layer with three wounds[1].
Aflibercept (500 μg/mL; 7 d) displays a significantly diminished phagocytosis of opsonised latex beads compared to untreated control[1].
Aflibercept (1 and 10 μg/mL; 10 h) inhibits VEGF signaling by reducing VEGF-regulated processes, such as permeability and angiogenesis[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Aflibercept (10 mg/kg; 3 h post-middle cerebral artery occlusion (MCAO)) reduces stroke-induced VEGF-A and VEGFR2 expression, and brain edema, and BBB disruption and improves poststroke survival in obese mice[2].
Aflibercept (18.2 mg/kg and 36.4 mg/kg; i.v. once) affects BP, ROS and eNOS production in mice[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6 mice[3]
Dosage: 18.2 mg/kg and 36.4 mg/kg
Administration: Intravenous injection; 18.2 mg/kg and 36.4 mg/kg once
Result: Rapidly and dose-dependently elevated BP in mice and markedly impaired endothelial-dependent relaxation (EDR) and resulted in NADPH oxidases 1 (NOX1)- and NADPH oxidases 4 (NOX4)-mediated generation of ROS, decreased the activation of protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) concurrently with a reduction in nitric oxide (NO) production and elevation of ET-1 levels in mouse aortas.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料

纯度: ≥97.0%

参考文献

Aflibercept 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Aflibercept
目录号:
HY-108801
需求量: